Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Trial suggests effectiveness of psilocybin for cocaine use disorderThe Brown University Psychopharmacology Update · 2026-08-31Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-04Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.Molecular Psychiatry · 2026-08-03Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-08-03Simulated 5-HT2A receptor activation accounts for the high complexity of brain activity during psychedelic statesbioRxiv · 2026-08-03Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networksNature Communications · 2026-08-02Music for Psilocybin Therapy and the Temporal Arc of Psychedelic ExperienceResearch Square · 2026-08-02Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.Journal of Pain and Symptom Management · 2026-08-02Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-02Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-08-02Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-01Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.Unknown journal · 2026-07-31Psilocybin for Fear of Cancer Recurrence.Supportive Care in Cancer · 2026-07-31One Dose of Psilocybin May Alter Brain StructurePsychiatric News · 2026-07-31Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.Unknown journal · 2026-07-31From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.The Lancet regional health. Europe · 2026-07-31Phase 1 trial suggests benefit of psilocybin in OCD treatmentThe Brown University Psychopharmacology Update · 2026-07-31Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.Journal of psychopharmacology (Oxford, England) · 2026-07-31Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review.Unknown journal · 2026-07-31In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin.Archives of toxicology · 2026-07-31Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms.Behavioural pharmacology · 2026-07-31A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.Journal of psychopharmacology (Oxford, England) · 2026-07-31Classic psychedelics and personality: An updated systematic review.Journal of psychopharmacology (Oxford, England) · 2026-07-31Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.Drugs · 2026-07-31Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.Hearing research · 2026-07-31Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depressionPharmacological Research · 2026-07-31Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders.Clinical therapeutics · 2026-07-31Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026-07-31Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysisJournal of Affective Disorders · 2026-07-31The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-07-31A25-year analysis of Armillaria (honey mushroom) poisoning in Wisconsin.The American journal of emergency medicine · 2026-07-31Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.Drug and alcohol dependence · 2026-07-31A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.The International journal on drug policy · 2026-07-31The Experience-Trajectory Framework: Substance-Specific Risk Stratification for Psychedelic Preparation and Aftercare Beyond Set and SettingInternational Journal For Multidisciplinary Research · 2026-07-30A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-30Retreat from racism: A psychedelic group experience for racial stress and traumaPsychedelics · 2026-07-29Beyond psilocybin: Do magic mushroom preparations contain other compounds with pharmacological effects?Authorea Preprints · 2026-07-29Shrooming Ahead: How the U.S. is Marching Toward Psilocybin Legalization and What Other Countries May LearneYLS (Yale Law School) · 2026-07-29Childhood trauma and psychological outcomes following psychedelic use: a scoping reviewnpj Mental Health Research · 2026-07-29Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionClinicalTrials.gov · 2026-07-29Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-07-29Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial.Communications Medicine · 2026-07-29Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-29Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-07-29Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-07-29Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-07-29Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from JamaicaFrontiers in Psychiatry · 2026-07-28TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-07-28TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-07-28An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSDClinicalTrials.gov · 2026-07-28NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-07-28Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-07-28Is BOLD Measurement-Invariant Across Pharmacological State? A Pre-Registered Test of Haemodynamic Response Function Drug-Invariance Using Simultaneous EEG-fMRI (PsiConnect)Open MIND · 2026-07-27A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in DepressionUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2026-07-27Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.Molecular Psychiatry · 2026-07-27Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.ClinicalTrials.gov · 2026-07-27Network Pharmacology-Guided Discovery of Fungal Autophagy Modulators for Tauopathies: Structural and Proteomic EvidencebioRxiv · 2026-07-27Identifying factors that contribute to the behavioral effects of psilocybin in preclinical mouse modelsbioRxiv · 2026-07-27Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex.Psychopharmacology · 2026-07-27Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.Unknown journal · 2026-07-27Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-27[Illicit use of classic psychedelics and suicidality: A systematic literature review].Unknown journal · 2026-07-26Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.Journal of music therapy · 2026-07-23Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-07-23An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-07-23Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-07-23Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.Molecular Psychiatry · 2026-07-23Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when?Expert Review of Neurotherapeutics · 2026-07-22Estimating Cardiac 5-HT2B Safety Margins for Repeated Low-Dose Psilocybin Using an Exposure-Response ModelbioRxiv · 2026-07-22No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study.Journal of Psychopharmacology · 2026-07-22A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-22Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-22Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)ClinicalTrials.gov · 2026-07-22A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-22A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-22The "dark magic mushroom" co-produces amatoxins and psilocybinbioRxiv · 2026-07-21Longitudinal neural and psychological changes following psilocybin under compassion imagery primingFrontiers in Human Neuroscience · 2026-07-21Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.Unknown journal · 2026-07-20Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertaintybioRxiv · 2026-07-20PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-20Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-07-20Psilocybin restores behavior and 5-HT signaling while reducing microglial density after chronic traumatic brain injury in rats.Cell reports. Medicine · 2026-07-20Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptorsbioRxiv · 2026-07-19Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosisFrontiers in Public Health · 2026-07-19The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-07-19A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults.medRxiv · 2026-07-18Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurementPsychedelics · 2026-07-17Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology · 2026-07-17Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-16A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-16Publication bias in randomized trials of psilocybin for depression: a Robust Bayesian Meta-AnalysisPsyArXiv · 2026-07-16Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-07-16The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderClinicalTrials.gov · 2026-07-16Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-15Integrated 5-HT2A-TrkB and G protein signaling in serotonergic psychedelic responses.Unknown journal · 2026-07-15Uncovering the spatiotemporal structure of neural avalanches through optimal transport and dynamic time warpingbioRxiv · 2026-07-15Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.Journal of Psychopharmacology · 2026-07-15Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-07-15Sex-dependent effects of psychedelics: review of evidence from rodent modelsFrontiers in Psychiatry · 2026-07-14The ANCHOR Framework for Psychedelic AccompanimentPsyArXiv · 2026-07-14Psilocybin's effect on human brain synaptic plasticity.Translational Psychiatry · 2026-07-14Shurooms: The First Ethnomycological Study from Within the African Initiatory Tradition - Ewe, Soma, and the Ceremonial Architecture of Psilocybin Healing (N = 300+)Zenodo (CERN European Organization for Nuclear Research) · 2026-07-13Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-13Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot StudymedRxiv · 2026-07-13Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.Unknown journal · 2026-07-12Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female ParticipantsbioRxiv · 2026-07-12Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overviewJournal of Psychedelic Studies · 2026-07-12Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-12Psilocybin-induced behavioral and cellular effects.Journal of Neurogenetics · 2026-07-11National bill seeks to jump-start psychedelic treatment for veteransAlcoholism & Drug Abuse Weekly · 2026-07-10Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation.Unknown journal · 2026-07-09Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology · 2026-07-09PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-09PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-09Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainClinicalTrials.gov · 2026-07-09Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signalingbioRxiv · 2026-07-08Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol.Open MIND · 2026-07-08The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-08First molecular record of Panaeolus subbalteatus (Psathyrellaceae, Agaricales) from Pakistan.Unknown journal · 2026-07-08Psychedelics stores, their regulation and public health: knowledge, perceptions, attitudes and opinions of Canadians.Unknown journal · 2026-07-08Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-08Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-08Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use DisorderClinicalTrials.gov · 2026-07-08Dissociating the Hallucinogenic and Neuroplastic Effects of PsilocybinbioRxiv · 2026-07-08Entourage-Psilocybin-GanzpilzZenodo (CERN European Organization for Nuclear Research) · 2026-07-07Entourage-Psilocybin-GanzpilzZenodo (CERN European Organization for Nuclear Research) · 2026-07-07Psilocybin therapy for adult females with anorexia nervosa: pilot study.The British Journal of Psychiatry · 2026-07-07Synthesis and Biological Evaluation of 4-Bromo-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.ACS omega · 2026-07-06α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice.Molecular Psychiatry · 2026-07-06CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.Neuropsychopharmacology · 2026-07-06Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026).Journal of Psychopharmacology · 2026-07-06Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-06Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)ClinicalTrials.gov · 2026-07-06Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-07-06The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer.BMC Medicine · 2026-07-05A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-07-05Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case ReviewMexican Journal of Medical Research ICSA · 2026-07-04Pupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states.Journal of neuroscience methods · 2026-07-03Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-02Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-02Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled ConditionsJournal of Fungi · 2026-07-01Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?Journal of Science Policy & Governance · 2026-07-01Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.International Journal of Eating Disorders · 2026-07-01Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019Research Square · 2026-07-01Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-07-01Unmixing the psychedelic connectome: Brain network traits of psilocybinNetwork Neuroscience · 2026-07-01Psilocybin helps woman with Alzheimer'sNew Scientist · 2026-06-30Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?EcoEvoRxiv · 2026-06-30Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health SymptomsJournal of Drug Issues · 2026-06-30Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.Unknown journal · 2026-06-30Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-06-30A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-30Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Unknown journal · 2026-06-30Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic reviewJournal of Affective Disorders Reports · 2026-06-30Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.Unknown journal · 2026-06-30Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.Palliative medicine · 2026-06-30MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.Unknown journal · 2026-06-30Psilocybin as a novel treatment for chronic pain.British journal of pharmacology · 2026-06-30The Australia story: Current status and future challenges for the clinical applications of psychedelics.British journal of pharmacology · 2026-06-30Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.British journal of pharmacology · 2026-06-30Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.British journal of pharmacology · 2026-06-30Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?British journal of pharmacology · 2026-06-30Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.British journal of pharmacology · 2026-06-30Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice.Unknown journal · 2026-06-30Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-06-30Three cases of wood-lover paralysis: clinical insights from Victoria, Australia.Clinical toxicology (Philadelphia, Pa.) · 2026-06-30Psychedelics as a potential treatment for borderline personality disorder: A narrative review.Psychiatry research · 2026-06-30Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-06-30The relevance of the 5HT2A-mGlu2 heterodimer in explaining the clinical ambivalence of psilocybinRevista de Neuro-Psiquiatría · 2026-06-29Study Protocol for "Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults".PLoS ONE · 2026-06-29Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.Unknown journal · 2026-06-29Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets.Proceedings of the National Academy of Sciences of the United States of America · 2026-06-29Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Unknown journal · 2026-06-29Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-28MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen nextUnknown journal · 2026-06-285-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-28Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.Journal of Psychopharmacology · 2026-06-27Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-25Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitaloprambioRxiv · 2026-06-25The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping reviewJournal of Psychopharmacology · 2026-06-25Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-24A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-24Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-06-24The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.Journal of psychopharmacology (Oxford, England) · 2026-06-24Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Unknown journal · 2026-06-24Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health careTranslational Psychiatry · 2026-06-23Multi-metric evaluations of acute psychedelic effects on fMRI brain entropyNature Communications · 2026-06-23Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challengesJournal of Psychiatric Research · 2026-06-22Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-06-22Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22Psilocybin-Assisted Therapy for Prolonged GriefClinicalTrials.gov · 2026-06-22Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.Clinical toxicology (Philadelphia, Pa.) · 2026-06-22Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-06-21Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-21Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-21Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1Unknown journal · 2026-06-20Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment OutcomesResearch Square · 2026-06-18